TEL AVIV, Israel — October 7, 2026
SciSparc announced that its majority-owned subsidiary NeuroThera Labs’ subsidiary CliniQuantum reported successful quantum-enabled computational analysis of billions of gene combinations using real-world clinical data. CliniQuantum’s GPU-accelerated quantum-simulation platform achieved approximately 16.8-fold computational acceleration using a single 64-core x86_64 machine equipped with one NVIDIA T4 Tensor Core GPU, compared with CPU-only processing on the same 64-vCPU configuration. The benchmark demonstrates a potential computational pathway for processing highly dimensional biomedical datasets, although the evaluation was designed to measure computational performance rather than establish clinical validity or predictive utility.
Platform Analyzed More Than 7.3 Billion Gene Triplets
The evaluation used a real-world clinical gene-expression dataset involving 11 patients and 3,531 gene-expression features, creating a challenging environment in which the number of biological variables substantially exceeded the number of patient samples. CliniQuantum’s algorithm searched for correlated three-gene configurations across the dataset. The 3,531 genes generated approximately 7.33 billion possible three-gene combinations, of which the algorithm identified approximately 22.2 million correlated gene triplets using a predefined minimum correlation threshold. The analysis produced the same qualifying gene-triplet results in both CPU and GPU-accelerated implementations.
GPU Quantum Simulation Cuts Computational Time
According to the company, the full analysis required approximately 8.4 hours using 64 virtual CPUs, while the GPU-accelerated implementation completed the same computation in approximately 0.5 hours using a single NVIDIA T4 GPU. The benchmark was performed on an AWS g4dn.16xlarge EC2 machine using IBM Qiskit Aer GPU-based quantum simulation technology. SciSparc said the approximately 16.8-fold acceleration highlights the potential of GPU-enabled quantum simulation for computationally demanding biomedical analyses. However, the company emphasized that the benchmark does not demonstrate that the identified gene combinations have clinical significance, predictive value or therapeutic utility.
Advertisement
CliniQuantum Advances Toward Quantum Computing Hardware
CliniQuantum plans to continue developing its algorithms for larger biomedical datasets and increasingly complex multi-feature configurations. The company also intends to progress its technology from simulation and computational validation toward execution on quantum computing hardware. The work is being pursued through NeuroThera Labs, a clinical-stage pharmaceutical company focused on novel treatments for central nervous system and other underserved conditions. SciSparc’s broader development portfolio includes cannabinoid-based programs such as SCI-110 for Tourette syndrome and Alzheimer’s disease-related agitation, and SCI-210 for autism spectrum disorder and status epilepticus. The latest CliniQuantum milestone represents a computational development step rather than a clinical or therapeutic efficacy finding.
Source::SciSparc, press release
